Selected article for: "adverse event and CT scan"
Author: Dipasquale, Angelo; Persico, Pasquale; Lorenzi, Elena; Rahal, Daoud; Santoro, Armando; Simonelli, Matteo
Title: COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report
  • Cord-id: upl5rb47
  • Document date: 2021_2_11
    • ID: upl5rb47
    Snippet: By the beginning of the global pandemic, SARS-CoV-2 infection has dramatically impacted on oncology daily practice. In the current oncological landscape, where immunotherapy has revolutionized the treatment of several malignancies, distinguishing between COVID-19 and immune-mediated pneumonitis can be hard because of shared clinical, radiological and pathological features. Indeed, their common mechanism of aberrant inflammation could lead to a mutual and amplifying interaction. We describe the c
    Document: By the beginning of the global pandemic, SARS-CoV-2 infection has dramatically impacted on oncology daily practice. In the current oncological landscape, where immunotherapy has revolutionized the treatment of several malignancies, distinguishing between COVID-19 and immune-mediated pneumonitis can be hard because of shared clinical, radiological and pathological features. Indeed, their common mechanism of aberrant inflammation could lead to a mutual and amplifying interaction. We describe the case of a 65–year-old patient affected by metastatic squamous head and neck cancer and candidate to an experimental therapy including an anti-PD-L1 agent. COVID-19 ground-glass opacities under resolution were an incidental finding during screening procedures and worsened after starting immunotherapy. The diagnostic work-up was consistent with ICIs-related pneumonia and it is conceivable that lung injury by SARS-CoV-2 has acted as an inflammatory primer for the development of the immune-related adverse event. Patients recovered from COVID-19 starting ICIs could be at greater risk of recall immune-mediated pneumonitis. Nasopharyngeal swab and chest CT scan are recommended before starting immunotherapy. The awareness of the phenomenon could allow an easier interpretation of radiological changes under treatment and a faster diagnostic work-up to resume ICIs. In the presence of clinical benefit, for asymptomatic ICIs-related pneumonia a watchful-waiting approach and immunotherapy prosecution are suggested.

    Search related documents:
    Co phrase search for related documents
    • absolute lymphocyte count and acute phase: 1
    • absolute lymphocyte count and adjuvant treatment: 1
    • acceptable risk and action mechanism: 1
    • acceptable risk and local disease: 1, 2
    • acceptable risk and local disease progression: 1
    • action mechanism and acute phase: 1, 2, 3, 4
    • action mechanism and adjuvant treatment: 1, 2
    • action mechanism and local disease: 1
    • action mechanism and lung damage: 1, 2, 3, 4, 5, 6
    • active infection and acute phase: 1, 2, 3, 4, 5, 6, 7
    • active infection and adjuvant treatment: 1
    • active infection and local disease: 1
    • active infection and lung biopsy: 1
    • active infection and lung damage: 1, 2, 3, 4, 5, 6
    • activity safety and acute phase: 1, 2
    • activity safety and lung biopsy: 1
    • acute phase and local disease: 1, 2, 3
    • acute phase and lung biopsy: 1, 2, 3, 4
    • acute phase and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20